SCHEMBL763447

SCHEMBL763447

Cc1ccc(OCCCCn2cncn2)cc1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.64
MAPT P10636 4/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
LMNA P02545 3/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
KDM4E B2RXH2 1/20 0.63
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
TP53 P04637 2/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
HPGD P15428 1/20 0.60
ALOX15 P16050 1/20 0.60
MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12835272 0.98 ALDH1A1 (0.62) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL12834842 0.95 MAPT (0.69) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL13246375 0.91 SMN1; SMN2 (0.77) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL16314569 0.84 MAPT (0.62) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL16417992 0.81 SMN1; SMN2 (0.67) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL20273277 0.81 CYP19A1 (0.55) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL16358909 0.80 MAPT (0.69) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL16359672 0.80 MAPT (0.69) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL10789133 0.80 SMN1; SMN2 (0.70) ALDH1A1MAPTSMN1; SMN2LMNAMEN1
SCHEMBL8995256 0.78 MAPT (0.66) ALDH1A1MAPTSMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 US disclosed
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS PTC THERAPEUTICS, INC. 2010-07-15 US disclosed
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2010-06-24 US disclosed
US-7601840-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2009-10-13 US disclosed
WO-2008127715-A1 CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. (US) 2008-10-23 WO disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES RNMT, VEGFA, VHL ALDH1A1 1851/4885MAPT 3101/4885SMN1; SMN2 1436/4885
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration VEGFA, FLT4, MIF ALDH1A1 1537/4885MAPT 2854/4885SMN1; SMN2 4645/4885
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS VEGFA, FLT4, PGF ALDH1A1 1035/4885MAPT 4804/4885SMN1; SMN2 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.